DOP2014000141A - Derivados de quinolina como inhibidores de la enzima pde10a - Google Patents

Derivados de quinolina como inhibidores de la enzima pde10a

Info

Publication number
DOP2014000141A
DOP2014000141A DO2014000141A DO2014000141A DOP2014000141A DO P2014000141 A DOP2014000141 A DO P2014000141A DO 2014000141 A DO2014000141 A DO 2014000141A DO 2014000141 A DO2014000141 A DO 2014000141A DO P2014000141 A DOP2014000141 A DO P2014000141A
Authority
DO
Dominican Republic
Prior art keywords
inhibitors
derivatives
quinoline
compounds
pde10a
Prior art date
Application number
DO2014000141A
Other languages
English (en)
Inventor
Jan Kehler
Morten Langgard
Jacob Nielsen
John Paul Kilburn
Ask Puschl
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48667762&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2014000141(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of DOP2014000141A publication Critical patent/DOP2014000141A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona derivados de quinolina de fórmula I que son inhibidores de la enzima PDE10A y, como tales, son útiles para tratar trastornos psiquiátricos y neurodegenerativos. En especial, la invención proporciona compuestos que son altamente selectivos para PDE10 respecto de otros subtipos de PDE. La presente invención proporciona además composiciones farmacéuticas que comprenden compuestos de la invención y métodos para tratar trastornos empleando los compuestos de la invención.
DO2014000141A 2011-12-21 2014-06-17 Derivados de quinolina como inhibidores de la enzima pde10a DOP2014000141A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161578320P 2011-12-21 2011-12-21
DKPA201100990 2011-12-21

Publications (1)

Publication Number Publication Date
DOP2014000141A true DOP2014000141A (es) 2014-07-31

Family

ID=48667762

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000141A DOP2014000141A (es) 2011-12-21 2014-06-17 Derivados de quinolina como inhibidores de la enzima pde10a

Country Status (32)

Country Link
US (2) US9216986B1 (es)
EP (1) EP2794606A1 (es)
JP (1) JP6073918B2 (es)
KR (1) KR20140105574A (es)
CN (1) CN104114554A (es)
AP (1) AP2014007697A0 (es)
AR (1) AR089361A1 (es)
AU (1) AU2012356885B2 (es)
BR (1) BR112014015192A8 (es)
CA (1) CA2859702A1 (es)
CL (1) CL2014001643A1 (es)
CO (1) CO6990727A2 (es)
CR (1) CR20140289A (es)
DO (1) DOP2014000141A (es)
EA (1) EA028824B1 (es)
EC (1) ECSP14010000A (es)
GE (1) GEP201706657B (es)
HK (1) HK1202861A1 (es)
IL (1) IL233226A (es)
MA (1) MA35860B1 (es)
MD (1) MD20140070A2 (es)
MX (1) MX348792B (es)
MY (1) MY165216A (es)
PE (1) PE20141945A1 (es)
PH (1) PH12014501434A1 (es)
RU (1) RU2624440C2 (es)
SG (1) SG11201403339YA (es)
TN (1) TN2014000268A1 (es)
TW (1) TWI570124B (es)
UA (1) UA111871C2 (es)
WO (1) WO2013092974A1 (es)
ZA (1) ZA201404533B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR089361A1 (es) 2011-12-21 2014-08-20 Lundbeck & Co As H Derivados de quinolina como inhibidores de la enzima pde10a
CA2889906A1 (en) * 2012-11-29 2014-06-05 Sunovion Pharmaceuticals Inc. Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
US20070105840A1 (en) 2003-06-30 2007-05-10 Altana Pharma Ag Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
AU2004253694A1 (en) 2003-06-30 2005-01-13 4Sc Ag Novel pyrrolodihydroisoquinolines useful in the treatment of cancer
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
CA2556413A1 (en) 2004-02-18 2005-09-09 Pfizer Products Inc. Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
EP1755611A1 (en) 2004-06-07 2007-02-28 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
AU2005282721A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
EP2565191B1 (en) 2008-05-14 2014-10-08 Astellas Pharma Inc. 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
UA102693C2 (ru) 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
JP2011201873A (ja) * 2010-03-03 2011-10-13 Mitsubishi Tanabe Pharma Corp 三置換ピリミジン化合物及びそのｐｄｅ１０阻害薬としての使用
CN103038229B (zh) * 2010-05-26 2016-05-11 桑诺维恩药品公司 杂芳基化合物及其使用方法
AR089361A1 (es) 2011-12-21 2014-08-20 Lundbeck & Co As H Derivados de quinolina como inhibidores de la enzima pde10a

Also Published As

Publication number Publication date
AU2012356885B2 (en) 2016-09-08
HK1202861A1 (en) 2015-10-09
MY165216A (en) 2018-03-09
MX348792B (es) 2017-06-29
EA201491152A1 (ru) 2015-01-30
CL2014001643A1 (es) 2014-11-21
GEP201706657B (en) 2017-04-25
PH12014501434B1 (en) 2014-09-22
BR112014015192A2 (pt) 2017-06-13
IL233226A0 (en) 2014-08-31
ECSP14010000A (es) 2015-12-31
CR20140289A (es) 2014-08-18
PE20141945A1 (es) 2014-12-18
IL233226A (en) 2017-11-30
EP2794606A1 (en) 2014-10-29
RU2014127984A (ru) 2016-02-10
AU2012356885A1 (en) 2014-07-10
CN104114554A (zh) 2014-10-22
US9216986B1 (en) 2015-12-22
RU2624440C2 (ru) 2017-07-04
US9801878B2 (en) 2017-10-31
KR20140105574A (ko) 2014-09-01
SG11201403339YA (en) 2014-07-30
US20160303120A1 (en) 2016-10-20
AP2014007697A0 (en) 2014-06-30
TN2014000268A1 (en) 2015-09-30
MX2014007409A (es) 2014-08-01
UA111871C2 (uk) 2016-06-24
CO6990727A2 (es) 2014-07-10
NZ626279A (en) 2015-07-31
JP2015502970A (ja) 2015-01-29
MA35860B1 (fr) 2014-12-01
ZA201404533B (en) 2015-12-23
WO2013092974A1 (en) 2013-06-27
CA2859702A1 (en) 2013-06-27
EA028824B1 (ru) 2018-01-31
BR112014015192A8 (pt) 2017-06-13
MD20140070A2 (ro) 2014-12-31
TWI570124B (zh) 2017-02-11
US20150376186A1 (en) 2015-12-31
AR089361A1 (es) 2014-08-20
JP6073918B2 (ja) 2017-02-01
PH12014501434A1 (en) 2014-09-22
TW201339156A (zh) 2013-10-01

Similar Documents

Publication Publication Date Title
GT201200180A (es) Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a
CU20130115A7 (es) Compuestos y composiciones como inhibidores de trk
GT201200171A (es) Derivados de fenilimidazol heteroaromáticos como inhibidores de enzima pde10a
GT201400196A (es) Compuestos de heterociclilo
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
CR20150524A (es) Compuestos de heteroarilo y sus usos
ECSP14013284A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
GT201400086A (es) Compuestos con actividad nematicida
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
CR20140481A (es) Compuestos triazolo como inhibidores de pde10
EA201491013A1 (ru) Пиразиновые ингибиторы киназы
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
CR20150248A (es) Derivados de oxazolidin-2-ona-pirimidina
IN2014CN03062A (es)
EA201590372A1 (ru) Бициклические гетероарилциклоалкилдиаминовые производные в качестве ингибиторов тирозинкиназ селезенки (syk)
BR112014016146A2 (pt) derivados de imidazopiridina como um inibidor de tirosina quinase
DOP2014000141A (es) Derivados de quinolina como inhibidores de la enzima pde10a
MY168958A (en) Intermediates and processes for preparing compounds
CU20140102A7 (es) Compuestos de oxazolidin-2- ona y usos de los mismos como inhibidores de la p13ks
CU20120052A7 (es) Derivados de pirazol que modulan estearoil-coa-desaturasa